E15 VC

Philip Liang, the firm's Managing Partner, leads all investment decisions. Liang founded E15 VC in 2018 and structured the firm around a concentrated portfolio model, meaning he personally underwrites every deal. The firm has not disclosed other general partners or an investment committee beyond Liang.

E15 VC focuses on pre-seed and seed-stage rounds, writing first institutional checks typically between $500,000 and $2 million. The firm aims to lead or co-lead rounds in a small number of companies per fund cycle, reflecting a high-conviction, concentrated deployment model rather than a spray-and-pray approach.

E15 VC invests across both Asia and the United States, a deliberate cross-border strategy uncommon among seed-stage firms of its size. Its Asian focus centers on Hong Kong, Singapore, and India, while US investments target major technology hubs. The firm argues early-stage technical talent is increasingly borderless and sources accordingly.

The firm relies heavily on founder referrals and technical community networks rather than institutional gatekeepers or broker-sourced deal flow. Philip Liang's personal connectivity — built through operating experience and regional presence — forms the backbone of sourcing, making the pipeline highly path-dependent on his relationships and reputation among technical founders.

E15 VC deploys exclusively through direct equity investments in portfolio companies. There is no public record of the firm making fund-of-fund commitments or investing as a limited partner in other venture firms. Its strategy is built entirely around direct early-stage exposure.

E15 VC actively co-invests alongside external GPs, consistent with its seed-stage strategy of leading or co-leading rounds. The firm has not established a formalized co-investor club or syndicate structure, but its investment activity is intermediated through founder introductions, suggesting opportunistic co-investment with other early-stage investors.

E15 VC has not published an explicit sector exclusion list. However, its disclosed investment activity concentrates almost entirely on enterprise software, AI/ML, fintech, and digital health. Sectors with heavy physical infrastructure, regulatory barriers, or long development cycles — such as hardtech manufacturing, traditional energy, and biopharma — appear absent from its observed portfolio.